Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    F-627 | Phase 3

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03252431
Recruitment Status : Completed
First Posted : August 17, 2017
Last Update Posted : July 17, 2020
Sponsor:
Information provided by (Responsible Party):
Generon (Shanghai) Corporation Ltd.

Tracking Information
First Submitted Date  ICMJE August 14, 2017
First Posted Date  ICMJE August 17, 2017
Last Update Posted Date July 17, 2020
Actual Study Start Date  ICMJE February 28, 2018
Actual Primary Completion Date September 25, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 14, 2017)
Duration in days of grade 4 neutropenia in chemotherapy cycle 1 [ Time Frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) ]
The primary endpoint is the duration of grade 4 (severe) neutropenia (ANC < 0.5 x 109/L) defined as the number of days in which the subject has had an ANC < 0.5 × 109/L during cycle 1 of their chemotherapy treatment.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 14, 2017)
  • Duration in days of use of intravenous antibiotic [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The duration of use of intravenous (IV) antibiotics (total across all chemotherapy cycles).
  • Duration in days of hospitalization [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The duration in days of patients been hospitalized for febrile neutropenia (FN) or any infection. Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of >38.0°C (100.4°F) sustained for >1 hour and ANC <0.5 x 10^9/L on the same day.
  • The incidence of grade 4 neutropenia for chemotherapy cycle 1 [ Time Frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) ]
    The incidence of grade 4 neutropenia for chemotherapy cycle 1
  • The incidence of febrile neutropenia [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The incidence of febrile neutropenia, considering all chemotherapy cycles.
  • The incidence of hospitalization for febrile neutropenia or any infection [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.
  • The incidence of use of IV antibiotics [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The incidence of use of IV antibiotics, considering all 4 chemotherapy cycles.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Official Title  ICMJE A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Brief Summary This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive breast cancer receiving chemotherapy treatment.
Detailed Description

This is a Phase III, global, two arm, open label clinical study will randomize approximately 400 female subjects (approximately 200 per arm) with Stage I - III invasive breast cancer who are to receive neoadjuvant or adjuvant myelotoxic TC chemotherapy treatment (docetaxel + cyclophosphamide, 75 and 600 mg/m2, respectively). Subjects in this study will be those who are scheduled to undergo at least four 21-day cycles of chemotherapy treatment. Subjects may be scheduled for more than 4 cycles of chemotherapy; however, study participation will be limited to a subject's first 4 cycles.

The primary objective of this study will be to evaluate the efficacy of F-627 given as a single fixed dose (20 mg) pre-filled syringe as compared to Neulasta® standard dosing (6 mg) in the first chemotherapy cycle. The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC <0.5 x 10^9/L) observed in chemotherapy cycle 1.

Approximately 24 hours after chemotherapy completion in each cycle (Day 2 of the cycle), subjects will receive one of the following treatments:

Arm 1: F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.

Arm 2: 6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles Randomization will occur in an equal ratio (1:1) using a central randomization system (IWRS) on Day 1 of the study, the day of chemotherapy administration for the first chemotherapy cycle.

This study is open-label, however, study drug injections are to be administered separately by qualified study personnel to allow study investigators to remain blinded and perform study assessments without knowledge of treatment assignment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Breast Cancer
  • Neutropenia
Intervention  ICMJE
  • Drug: F-627
    single dose pre-filled syringe
  • Drug: Neulasta
    single dose pre-filled syringe
    Other Name: pegfilgrastim
Study Arms  ICMJE
  • Experimental: F-627
    F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
    Intervention: Drug: F-627
  • Active Comparator: Neulasta
    6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
    Intervention: Drug: Neulasta
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 29, 2019)
393
Original Estimated Enrollment  ICMJE
 (submitted: August 14, 2017)
400
Actual Study Completion Date  ICMJE March 5, 2020
Actual Primary Completion Date September 25, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
  2. Females ≥18 years of age and <75 years of age.
  3. Diagnosed with Stage I-III breast cancer.
  4. Subject is scheduled to undergo 4 cycles of neoadjuvant or adjuvant TC chemotherapy (docetaxel, cyclophosphamide, 75, 600 mg/m2, respectively).
  5. ECOG Performance status of ≤2.
  6. WBC count ≥4.0 × 109/L, hemoglobin ≥11.5 g/dL and a platelet count ≥150 × 109/L.
  7. Demonstrate adequate renal, hepatic, and cardiac function (liver function tests [alanine aminotransferase {ALT}, aspartate aminotransferase {AST}, alkaline phosphatase, and total bilirubin]) should be less than 2.5x the upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.
  8. All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.

Exclusion Criteria:

  1. Subject is <18 or ≥75 years of age.
  2. Disease progression has occurred while receiving a taxane regimen.
  3. Subject has undergone radiation therapy within 4 weeks of enrollment.
  4. Subject has undergone bone marrow or stem-cell transplantation.
  5. Subject has a history of prior malignancy other than breast cancer that is NOT in remission.
  6. Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e., lithium) within 6 weeks of the screening period are excluded.
  7. Subject has had chemotherapy within 180 days of screening.
  8. Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, electrocardiogram (ECG) test, or any other relevant test.
  9. History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
  10. Unwillingness to participate in the study.
  11. Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
  12. Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment (if known), which ever is less.
  13. Any condition, which can cause splenomegaly.
  14. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
  15. ALT, AST, alkaline phosphatase, total bilirubin ≥2.5x ULN.
  16. Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.
  17. Women who are pregnant or breast-feeding.
  18. Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.
  19. Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
  20. Subjects with Sickle Cell disease
  21. Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 74 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03252431
Other Study ID Numbers  ICMJE GC-627-05
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Generon (Shanghai) Corporation Ltd.
Study Sponsor  ICMJE Generon (Shanghai) Corporation Ltd.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Generon (Shanghai) Corporation Ltd.
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP